About Technology Issues FAQ

Links

T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy

T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.